Found a bug or want a feature? Verified reports earn free credits.
Log inSign up
शुभ दीपावलीDiwali offer: 3 months free on yearly plans · ends 11 NovSee plans
Companies›Healthcare›Healthcare›Pharmaceuticals & Biotechnology

Parmax Pharma Limited

Healthcare › Pharmaceuticals & Biotechnology

Latest filings

  1. Major Fire At Parmax Pharma Plant In Rajkot; Two Employees Injured · Capex & Operations
  2. Annual Report FY2025-26 and Notice of 32nd AGM on Sept 29, 2026 · Board & Shareholder Meetings
  3. Parmax Pharma 32nd AGM on Sept 29, 2026 via video conferencing · Board & Shareholder Meetings
All filings ↓
Ask Nexa about Parmax Pharma Limited

Snapshot

What the business is, and whether it's a good one at a fair price.

A Pharmaceuticals & Biotechnology company listed on BSE, reporting revenue of ₹18 Cr over the trailing twelve months.

Market Cap
₹—
P / E (TTM)
—
EV / EBITDA
—
Div Yield
—
Growth
-14.3%▼
Revenue 5y CAGR
PAT — · EBITDA —
Quality
-31.7%·
ROCE (5y median)
ROE n/m · margin -30.0%
Leverage
n/m·
Debt / Equity · negative net worth
Net debt ₹11 Cr
Revenue FY21→FY26
0.5×▼
Margin −37.2 pts
₹26 Cr → ₹12 Cr
Where it sits among 185 Pharmaceuticals peersBar = share of peers beaten · tick = industry median · latest reported figures
ROCE#176/177
EBITDA margin#112/178
Revenue growth#4/163
Profit growth#11/157

Scorecard

Measured from the filed financials, judged against its Pharmaceuticals peers · as of FY26 — not investment advice

Strengths
Negative working-capital cycle — the business is funded by its suppliers
Concerns
Revenue shrinking over 5 years (−14% a year)
Erratic profits — up in only 1 of the last 5 years
Negative returns on capital — −31.7% (5-year median)
#176 of 177 in Pharmaceuticals on the latest reported figures · down from 13.6% in FY21
Negative net worth — liabilities exceed assets by ₹6.15 Cr (FY26)
Debt-to-equity and return on equity are not meaningful below zero equity
Customers are taking longer to pay — 23 → 95 days of receivables
FY21 → FY26

Charts

How has the market priced it — with filings on the timeline?

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Peers

How does it stack up on valuation, returns and growth?

Loading peers…

Financials

Quarterly & annual P&L, balance sheet, cash flow, ratios and segments.

Loading financials…

Ownership

Who owns it — and is the promoter stake clean?

Loading shareholding…

Sign up to see the full company file

Governance, sustainability, compliance, earnings calls, presentations, events, reactions and the full filings feed — free with an account.

Common questions

Answered from Parmax Pharma Limited's filed financials and exchange disclosures

What does Parmax Pharma Limited do?

Parmax Pharma Limited is a Pharmaceuticals & Biotechnology company listed on BSE.

Is Parmax Pharma Limited profitable?

No. Over the trailing twelve months Parmax Pharma Limited reported a net loss of ₹1.20 Cr on revenue of ₹18 Cr.

Does Parmax Pharma Limited pay a dividend?

Not in the latest reported year — Parmax Pharma Limited's dividend payout for FY26 was nil.

Is Parmax Pharma Limited debt-free?

No. It reported borrowings of ₹12 Cr on its 31 Mar 2026 balance sheet, or net debt of ₹11 Cr after cash. Its net worth is negative — liabilities exceed assets by ₹6.15 Cr, so a debt-to-equity ratio is not meaningful.

Where can I track Parmax Pharma Limited's announcements?

Every NSE and BSE filing by Parmax Pharma Limited appears on this page, AI-summarised, alongside the price reaction that followed it. Follow the company to get each new filing on WhatsApp within minutes.

Figures are as last reported and may lag the latest filing. Not investment advice.